Innate Pharma SA (IPHYF)
2.20
0.00 (0.00%)
USD |
OTCM |
May 09, 16:00
Innate Pharma Shareholders Equity (Quarterly): 57.37M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 57.37M |
| June 30, 2023 | 62.88M |
| June 30, 2023 | 62.88M |
| December 31, 2022 | 58.07M |
| June 30, 2022 | 121.52M |
| June 30, 2022 | 121.52M |
| December 31, 2021 | 121.65M |
| June 30, 2021 | 158.94M |
| June 30, 2021 | 158.94M |
| December 31, 2020 | 191.84M |
| June 30, 2020 | 233.67M |
| June 30, 2020 | 233.67M |
| December 31, 2019 | 243.54M |
| June 30, 2019 | 206.10M |
| June 30, 2019 | 206.10M |
| December 31, 2018 | 191.31M |
| June 30, 2018 | 100.79M |
| June 30, 2018 | 100.79M |
| December 31, 2017 | 103.12M |
| June 30, 2017 | 78.83M |
| June 30, 2017 | 78.83M |
| Date | Value |
|---|---|
| December 31, 2016 | 91.09M |
| June 30, 2016 | 76.98M |
| June 30, 2016 | 76.98M |
| December 31, 2015 | 78.79M |
| June 30, 2015 | 77.59M |
| June 30, 2015 | 77.59M |
| December 31, 2014 | 90.75M |
| June 30, 2014 | 115.99M |
| June 30, 2014 | 115.99M |
| December 31, 2013 | 55.63M |
| June 30, 2013 | 28.00M |
| June 30, 2013 | 28.00M |
| December 31, 2012 | 30.90M |
| June 30, 2012 | 30.66M |
| June 30, 2012 | 30.66M |
| December 31, 2011 | 34.49M |
| June 30, 2011 | 40.81M |
| December 31, 2010 | 44.57M |
| June 30, 2010 | 49.53M |
| December 31, 2009 | 67.38M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
57.37M
Minimum
Dec 2023
243.54M
Maximum
Dec 2019
149.25M
Average
158.94M
Median
Jun 2021
Shareholders Equity (Quarterly) Benchmarks
| DBV Technologies SA | 140.19M |
| Cellectis SA | 84.70M |
| PHAXIAM Therapeutics SA (DELISTED) | -- |
| Genfit SA | 75.11M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 203.61M |
| Total Liabilities (Quarterly) | 146.24M |
| Debt to Equity Ratio | 0.7525 |
| Current Ratio | 3.734 |
| Net Debt Paydown Yield | 0.31% |